Pioglitazone Accord

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
13-01-2022
Opinber matsskýrsla Opinber matsskýrsla (PAR)
17-05-2017

Virkt innihaldsefni:

pioglitazone hydrochloride

Fáanlegur frá:

Accord Healthcare S.L.U.

ATC númer:

A10BG03

INN (Alþjóðlegt nafn):

pioglitazone

Meðferðarhópur:

Drugs used in diabetes

Lækningarsvæði:

Diabetes Mellitus, Type 2

Ábendingar:

Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Vörulýsing:

Revision: 7

Leyfisstaða:

Authorised

Leyfisdagur:

2012-03-21

Upplýsingar fylgiseðill

                                31
B. PACKAGE LEAFLET
32
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PIOGLITAZONE ACCORD 15 MG TABLETS
PIOGLITAZONE ACCORD 30 MG TABLETS
PIOGLITAZONE ACCORD 45 MG TABLETS
Pioglitazone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICIN
e
BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pioglitazone Accord is and what it is used for
2.
What you need to know before you take Pioglitazone Accord
3.
How to take Pioglitazone Accord
4.
Possible side effects
5.
How to store Pioglitazone Accord
6.
Contents of the pack and other information
1.
WHAT PIOGLITAZONE ACCORD IS AND WHAT IT IS USED FOR
Pioglitazone Accord contains pioglitazone. It is an anti-diabetic
medicine used to treat type 2 (non-
insulin dependent) diabetes mellitus in adults, when metformin is not
suitable or has failed to work
adequately. This is the diabetes that usually develops in adulthood.
Pioglitazone Accord helps control the level of sugar in your blood
when you have type 2 diabetes by
helping your body make better use of the insulin it produces. Your
doctor will check whether
Pioglitazone Accord is working 3 to 6 months after you start taking
it.
Pioglitazone Accord may be used on its own in patients who are unable
to take metformin, and where
treatment with diet and exercise has failed to control blood sugar or
may be added to other therapies
(such as metformin, sulfonylurea or insulin) which have failed to
provide sufficient control of blood
sugar.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PIOGLITAZONE ACCORD
DO NOT TAKE PIOGLITAZONE ACCORD:
•
if you are allergic to pioglitazone 
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Pioglitazone Accord 15 mg tablets
Pioglitazone Accord 30 mg tablets
Pioglitazone Accord 45 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pioglitazone Accord 15 mg tablets
Each tablet contains 15 mg of pioglitazone (as hydrochloride).
_Excipient_
_ with known effect_
_: _
Each tablet contains 37.24 mg of lactose monohydrate (see section
4.4).
Pioglitazone Accord 30 mg tablets
Each tablet contains 30 mg of pioglitazone (as hydrochloride).
_Excipient with known effect: _
Each tablet contains 74.46 mg of lactose monohydrate (see section
4.4).
Pioglitazone Accord 45 mg tablets
Each tablet contains 45 mg of pioglitazone (as hydrochloride).
_Excipient_
_ with known effect_
_: _
Each tablet contains 111.70 mg of lactose monohydrate (see section
4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pioglitazone Accord 15 mg tablets
The tablets are white to off white, round, biconvex, uncoated tablets
debossed with ‘P’ on one side and
‘15’ on other side.
Pioglitazone Accord 30 mg tablets
The tablets are white to off white, flat, round uncoated tablets with
beveled edges debossed with ‘PIO’
on one side and ‘30’ on the other side.
Pioglitazone Accord 45 mg tablets
The tablets are white to off white, flat, round uncoated tablets with
beveled edges debossed with ‘PIO’
on one side and ‘45’ on the other side.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Pioglitazone is indicated as second or third line treatment of type 2
diabetes mellitus as described
below:
as
MONOTHERAPY
-
in adult patients (particularly overweight patients) inadequately
controlled by diet and
exercise for whom metformin is in appropriate because of
contraindications or
intolerance
as
DUAL ORAL THERAPY
in combination with
- metformin, in adult patients (particularly overweight patients) with
insufficient glycaemic control
despite maximal tolerated dose of monotherapy with metformin
- a sulphonylurea, only in
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 13-01-2022
Vara einkenni Vara einkenni búlgarska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla búlgarska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 13-01-2022
Vara einkenni Vara einkenni spænska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla spænska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 13-01-2022
Vara einkenni Vara einkenni tékkneska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla tékkneska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 13-01-2022
Vara einkenni Vara einkenni danska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla danska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 13-01-2022
Vara einkenni Vara einkenni þýska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla þýska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 13-01-2022
Vara einkenni Vara einkenni eistneska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla eistneska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 13-01-2022
Vara einkenni Vara einkenni gríska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla gríska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 13-01-2022
Vara einkenni Vara einkenni franska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla franska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 13-01-2022
Vara einkenni Vara einkenni ítalska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla ítalska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 13-01-2022
Vara einkenni Vara einkenni lettneska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla lettneska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 13-01-2022
Vara einkenni Vara einkenni litháíska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla litháíska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 13-01-2022
Vara einkenni Vara einkenni ungverska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla ungverska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 13-01-2022
Vara einkenni Vara einkenni maltneska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla maltneska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 13-01-2022
Vara einkenni Vara einkenni hollenska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla hollenska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 13-01-2022
Vara einkenni Vara einkenni pólska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla pólska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 13-01-2022
Vara einkenni Vara einkenni portúgalska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla portúgalska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 13-01-2022
Vara einkenni Vara einkenni rúmenska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla rúmenska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 13-01-2022
Vara einkenni Vara einkenni slóvakíska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 13-01-2022
Vara einkenni Vara einkenni slóvenska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla slóvenska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 13-01-2022
Vara einkenni Vara einkenni finnska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla finnska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 13-01-2022
Vara einkenni Vara einkenni sænska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla sænska 17-05-2017
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 13-01-2022
Vara einkenni Vara einkenni norska 13-01-2022
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 13-01-2022
Vara einkenni Vara einkenni íslenska 13-01-2022
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 13-01-2022
Vara einkenni Vara einkenni króatíska 13-01-2022
Opinber matsskýrsla Opinber matsskýrsla króatíska 17-05-2017

Leitaðu viðvaranir sem tengjast þessari vöru